Advertisement

Cellular Oncology

, Volume 36, Issue 3, pp 233–245 | Cite as

Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines

  • Yoshiki MukudaiEmail author
  • Seiji Kondo
  • Atsushi Fujita
  • Yasuto Yoshihama
  • Tatsuo Shirota
  • Satoru Shintani
Original Paper

Abstract

Purpose

Tumor protein D54 (TPD54) belongs to the TPD52 family of proteins and is expressed in several types of cancer, including oral squamous cell carcinoma (OSCC). Here, we investigated relationships between various OSCC-related characteristics and TPD54 expression in vitro.

Methods

The expression of TPD54 in several OSCC-derived cell lines and normal, non-malignant, cells was assessed. Based on the results obtained, OSCC-derived SAS cells were subsequently subjected to exogenous over-expression of alternative splice variants (ASVs) of TPD54 and to TPD54 knock-down, mediated by siRNA. Next, the role of TPD54 in cellular growth, apoptosis, invasion, migration and extracellular-matrix (ECM)-dependent migration and attachment was investigated, as also the concomitant expression of integrins and integrin-related proteins by the OSCC-derived cells.

Results

Western blot analysis and RT-PCR revealed that several TPD54 ASVs were expressed in the OSCC-derived cell lines tested. Neither exogenous ASV over-expression nor TPD54 knock-down modulated the proliferation or invasion of SAS cells in a monolayer culture assay. However, exogenous ASV over-expression did decrease anchorage-independent growth and TPD54 knock-down did increase anchorage-independent growth, irrespective of caspase activities. The same effects were observed on ECM-dependent cellular migration and cell attachment to the ECM. The expression levels of the major α and β integrin subunits, and of E-cadherin, were found to be similar to those observed in the non-transfected control cells, whereas talin1 expression was found to be increased after TPD54 knock-down. Also Akt was found to be activated after TPD54 knock-down, even in the absence of serum stimulation. Very similar effects were observed in the OSCC-derived cell lines HSC 2 and HSC 3.

Conclusions

Our results show that TPD54 affects OSCC cell attachment to the ECM, OSCC cell migration, and Akt/PKB activation by modulating integrin activation via a talin1-mediated inside-out signal of the ECM. Based on these results, we suggest that TPD54 may serve as a novel biomarker for OSCC and as a putative target for OSCC therapy.

Keywords

TPD54 TPD52 family Oral cancer Integrin Talin Akt ECM 

Notes

Acknowledgments

This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (to Y.M., S.K., T.S. and S.S.), and by the High-Technology Research Center Project from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to S.S.). The authors wish to thank Drs. Hiroaki Kamatani, Yasumasa Yoshizawa, Tomohiko Kutsuna Sayaka Yoshiba, Arisa Yasuda, Ryota Kishigami and Yuji and Sayaka Kurihara for their helpful suggestions, and to Ms. Miho Yoshihara for secretarial assistance.

Ethical standards

The experiments complied with the current laws of Japan.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. 1.
    S. Choi, J.N. Myers, Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 87, 14–32 (2008)PubMedCrossRefGoogle Scholar
  2. 2.
    C. Scully, J.V. Bagan, Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol. 45, e25–e30 (2009)PubMedCrossRefGoogle Scholar
  3. 3.
    H. Hamakawa, K. Nakashiro, T. Sumida et al., Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30, 800–809 (2008)PubMedCrossRefGoogle Scholar
  4. 4.
    R. Boutros, S. Fanayan, M. Shehata et al., The tumor protein D52 family: many pieces, many puzzles. Biochem. Biophys. Res. Commun. 325, 1115–1121 (2004)PubMedCrossRefGoogle Scholar
  5. 5.
    S. Alagaratnam, J.R. Hardy, R.A. Lothe et al., TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Mol. Cell. Endocrinol. 306, 75–80 (2009)PubMedCrossRefGoogle Scholar
  6. 6.
    D.D. Thomas, W.B. Taft, K.M. Kaspar et al., CRHSP-28 regulates Ca(2+)-stimulated secretion in permeabilized acinar cells. J. Biol. Chem. 276, 28866–28872 (2001)PubMedCrossRefGoogle Scholar
  7. 7.
    J.A. Byrne, M.G. Mattei, P. Basset, Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 35, 523–532 (1996)PubMedCrossRefGoogle Scholar
  8. 8.
    J.A. Byrne, M.G. Mattei, P. Basset et al., Identification and in situ hybridization mapping of a mouse Tpd52l1 (D53) orthologue to chromosome 10A4-B2. Cytogenet. Cell Genet. 81, 199–201 (1998)PubMedCrossRefGoogle Scholar
  9. 9.
    C.R. Nourse, M.G. Mattei, P. Gunning et al., Cloning of a third member of the D52 gene family indicates alternative coding sequence usage in D52-like transcripts. Biochim. Biophys. Acta 1443, 155–168 (1998)PubMedCrossRefGoogle Scholar
  10. 10.
    J.A. Byrne, C.R. Nourse, P. Basset et al., Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene 16, 873–881 (1998)PubMedCrossRefGoogle Scholar
  11. 11.
    R. Wang, J. Xu, O. Saramaki et al., PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res. 64, 1589–1594 (2004)PubMedCrossRefGoogle Scholar
  12. 12.
    Q. Cao, J. Chen, L. Zhu et al., A testis-specific and testis developmentally regulated tumor protein D52 (TPD52)-like protein TPD52L3/hD55 interacts with TPD52 family proteins. Biochem. Biophys. Res. Commun. 344, 798–806 (2006)PubMedCrossRefGoogle Scholar
  13. 13.
    J.A. Byrne, C. Tomasetto, J.M. Garnier et al., A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res. 55, 2896–2903 (1995)PubMedGoogle Scholar
  14. 14.
    S.L. Chen, I.G. Maroulakou, J.E. Green et al., Isolation and characterization of a novel gene expressed in multiple cancers. Oncogene 12, 741–751 (1996)PubMedGoogle Scholar
  15. 15.
    R.L. Malek, R.B. Irby, Q.M. Guo et al., Identification of Src transformation fingerprint in human colon cancer. Oncogene 21, 7256–7265 (2002)PubMedCrossRefGoogle Scholar
  16. 16.
    D.T. Petrova, A.R. Asif, V.W. Armstrong et al., Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin. Biochem. 41, 1224–1236 (2008)PubMedCrossRefGoogle Scholar
  17. 17.
    M.S. Fejzo, J. Dering, C. Ginther et al., Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer 47, 873–883 (2008)PubMedCrossRefGoogle Scholar
  18. 18.
    J.A. Byrne, R.L. Balleine, M. Schoenberg Fejzo et al., Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int. J. Cancer 117, 1049–1054 (2005)PubMedCrossRefGoogle Scholar
  19. 19.
    J.A. Byrne, S. Maleki, J.R. Hardy et al., MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 10, 497 (2010)PubMedCrossRefGoogle Scholar
  20. 20.
    A. Willems, K. De Gendt, J. Allemeersch et al., Early effects of Sertoli cell-selective androgen receptor ablation on testicular gene expression. Int. J. Androl. 33, 507–517 (2010)PubMedCrossRefGoogle Scholar
  21. 21.
    M.A. Rubin, S. Varambally, R. Beroukhim et al., Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 64, 3814–3822 (2004)PubMedCrossRefGoogle Scholar
  22. 22.
    M.J. Scanlan, I. Gout, C.M. Gordon et al., Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 1, 4 (2001)PubMedGoogle Scholar
  23. 23.
    T. Crugliano, B. Quaresima, M. Gaspari et al., Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation. Int. J. Biochem. Cell Biol. 39, 220–226 (2007)PubMedCrossRefGoogle Scholar
  24. 24.
    H. Chen, G. Pimienta, Y. Gu et al., Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics 10, 3800–3810 (2010)PubMedCrossRefGoogle Scholar
  25. 25.
    D. Barbaric, K. Byth, L. Dalla-Pozza et al., Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations. Leukemia Res. 30, 1355–1363 (2006)CrossRefGoogle Scholar
  26. 26.
    H. Kang, C.S. Wilson, R.C. Harvey et al., Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 119, 1872–1881 (2012)PubMedCrossRefGoogle Scholar
  27. 27.
    A. Marrone, P. Sokhal, A. Walne et al., Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 92, 1013–1020 (2007)PubMedCrossRefGoogle Scholar
  28. 28.
    E. Tiacci, P.L. Orvietani, B. Bigerna et al., Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood 105, 2812–2820 (2005)PubMedCrossRefGoogle Scholar
  29. 29.
    H.C. Cheung, K.A. Baggerly, S. Tsavachidis et al., Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 9, 216 (2008)PubMedCrossRefGoogle Scholar
  30. 30.
    J.D. Lewis, L.A. Payton, J.G. Whitford et al., Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol. Cancer Res. 5, 133–144 (2007)PubMedCrossRefGoogle Scholar
  31. 31.
    M. Azuma, T. Tamatani, Y. Kasai et al., Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection with SV40 ori- mutant deoxyribonucleic acid. Lab. Invest. 69, 24–42 (1993)PubMedGoogle Scholar
  32. 32.
    A. Yasuda, S. Kondo, T. Nagumo et al., Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol. 47, 334–339 (2011)PubMedCrossRefGoogle Scholar
  33. 33.
    M. Enomoto-Iwamoto, M. Iwamoto, Y. Mukudai et al., Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes. J. Cell Biol. 140, 409–418 (1998)PubMedCrossRefGoogle Scholar
  34. 34.
    H. Tsukamoto, S. Kondo, Y. Mukudai et al., Evaluation of anticancer activities of benzo[c]phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line. Anticancer. Res. 31, 2841–2846 (2011)PubMedGoogle Scholar
  35. 35.
    P. Sathasivam, A.M. Bailey, M. Crossley et al., The role of the coiled-coil motif in interactions mediated by TPD52. Biochem. Biophys. Res. Commun. 288, 56–61 (2001)PubMedCrossRefGoogle Scholar
  36. 36.
    R.O. Hynes, Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 (2002)PubMedCrossRefGoogle Scholar
  37. 37.
    M.A. Arnaout, S.L. Goodman, J.P. Xiong, Structure and mechanics of integrin-based cell adhesion. Curr. Opin. Cell Biol. 19, 495–507 (2007)PubMedCrossRefGoogle Scholar
  38. 38.
    D.A. Calderwood, B. Yan, J.M. de Pereda et al., The phosphotyrosine binding-like domain of talin activates integrins. J. Biol. Chem. 277, 21749–21758 (2002)PubMedCrossRefGoogle Scholar
  39. 39.
    D.A. Calderwood, R. Zent, R. Grant et al., The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J. Biol. Chem. 274, 28071–28074 (1999)PubMedCrossRefGoogle Scholar
  40. 40.
    A. Horwitz, K. Duggan, C. Buck et al., Interaction of plasma membrane fibronectin receptor with talin–a transmembrane linkage. Nature 320, 531–533 (1986)PubMedCrossRefGoogle Scholar
  41. 41.
    D. Zhang, D. He, Y. Xue et al., PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 71, 2193–2202 (2011)PubMedCrossRefGoogle Scholar
  42. 42.
    R. Ummanni, S. Teller, H. Junker et al., Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 275, 5703–5713 (2008)PubMedCrossRefGoogle Scholar
  43. 43.
    H. Zhang, J. Wang, B. Pang et al., PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res. 67, 8906–8913 (2007)PubMedCrossRefGoogle Scholar
  44. 44.
    G.E. Groblewski, M.J. Wishart, M. Yoshida et al., Purification and identification of a 28-kDa calcium-regulated heat-stable protein. A novel secretagogue-regulated phosphoprotein in exocrine pancreas. J. Biol. Chem. 271, 31502–31507 (1996)PubMedCrossRefGoogle Scholar
  45. 45.
    S.H. Wilson, A.M. Bailey, C.R. Nourse et al., Identification of MAL2, a novel member of the mal proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics 76, 81–88 (2001)PubMedCrossRefGoogle Scholar
  46. 46.
    R. Boutros, A.M. Bailey, S.H. Wilson et al., Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. J. Mol. Biol. 332, 675–687 (2003)PubMedCrossRefGoogle Scholar
  47. 47.
    J. Wang, H. Zhang, R.X. Liang et al., Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter. Biochem. Biophys. Res. Commun. 357, 8–13 (2007)PubMedCrossRefGoogle Scholar
  48. 48.
    R. Wang, J. Xu, N. Mabjeesh et al., PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin. Cancer Res. 13, 6040–6048 (2007)PubMedCrossRefGoogle Scholar
  49. 49.
    L. Li, D. Zhang, L. Zhang et al., PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol. Carcinog. 48, 432–440 (2009)PubMedCrossRefGoogle Scholar
  50. 50.
    R. Wang, H. He, X. Sun et al., Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins. Biochem. Biophys. Res. Commun. 389, 455–460 (2009)PubMedCrossRefGoogle Scholar
  51. 51.
    H. Zhao, C.J. Logothetis, I.P. Gorlov, Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. Prostate Cancer Prostatic Dis. 13, 252–259 (2010)PubMedCrossRefGoogle Scholar
  52. 52.
    G.E. Groblewski, M. Yoshida, H. Yao et al., Immunolocalization of CRHSP28 in exocrine digestive glands and gastrointestinal tissues of the rat. Am. J. Physiol. 276, G219–G226 (1999)PubMedGoogle Scholar
  53. 53.
    A.H. Sims, P. Finnon, C.J. Miller et al., TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. Int. J. Radiat. Biol. 83, 409–420 (2007)PubMedCrossRefGoogle Scholar
  54. 54.
    R. Boutros, J.A. Byrne, D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp. Cell Res. 310, 152–165 (2005)PubMedCrossRefGoogle Scholar
  55. 55.
    S. L’Esperance, I. Popa, M. Bachvarova et al., Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int. J. Oncol. 29, 5–24 (2006)PubMedGoogle Scholar
  56. 56.
    P. Zhao, W. Zhong, X. Ying et al., Comparative proteomic analysis of anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-transformed and normal human bronchial epithelial G0/G1 cells. Chem. Biol. Interact. 186, 166–173 (2010)PubMedCrossRefGoogle Scholar
  57. 57.
    G. Rennebeck, M. Martelli, N. Kyprianou, Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res. 65, 11230–11235 (2005)PubMedCrossRefGoogle Scholar
  58. 58.
    P. Chiarugi, E. Giannoni, Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 76, 1352–1364 (2008)PubMedCrossRefGoogle Scholar
  59. 59.
    A. Desiniotis, N. Kyprianou, Significance of talin in cancer progression and metastasis. Int. Rev. Cell. Mol. Biol. 289, 117–147 (2011)PubMedCrossRefGoogle Scholar
  60. 60.
    N.J. Anthis, I.D. Campbell, The tail of integrin activation. Trends Biochem. Sci. 36, 191–198 (2011)PubMedCrossRefGoogle Scholar
  61. 61.
    M. Moser, K.R. Legate, R. Zent et al., The tail of integrins, talin, and kindlins. Science 324, 895–899 (2009)PubMedCrossRefGoogle Scholar
  62. 62.
    J.M. Lewis, M.A. Schwartz, Mapping in vivo associations of cytoplasmic proteins with integrin beta 1 cytoplasmic domain mutants. Mol. Biol. Cell. 6, 151–160 (1995)PubMedGoogle Scholar
  63. 63.
    R. Rathinam, S.K. Alahari, Important role of integrins in the cancer biology. Cancer Metastasis Rev. 29, 223–237 (2010)PubMedCrossRefGoogle Scholar
  64. 64.
    M.T. Lai, C.H. Hua, M.H. Tsai et al., Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. J. Pathol. 224, 367–376 (2011)PubMedCrossRefGoogle Scholar
  65. 65.
    W.S. Wu, The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 25, 695–705 (2006)PubMedCrossRefGoogle Scholar
  66. 66.
    P.T. Bhaskar, N. Hay, The two TORCs and Akt. Dev. Cell 12, 487–502 (2007)PubMedCrossRefGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2013

Authors and Affiliations

  • Yoshiki Mukudai
    • 1
    Email author
  • Seiji Kondo
    • 1
  • Atsushi Fujita
    • 1
  • Yasuto Yoshihama
    • 1
  • Tatsuo Shirota
    • 1
  • Satoru Shintani
    • 1
  1. 1.Department of Oral and Maxillofacial Surgery, School of DentistryShowa UniversityTokyoJapan

Personalised recommendations